Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Influence of educational level on test and treatment for incident hypothyroidism

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Sex differences in acromegaly at diagnosis: A nationwide cohort study and meta-analysis of the literature

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Maternal thyroid disease and adiposity in mother and child

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Increased levels of inflammatory factors are associated with severity of polyneuropathy in type 1 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Long-term neurotoxicity and quality of life in testicular cancer survivors-a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Small RNAs in Seminal Plasma as Novel Biomarkers for Germ Cell Tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Late adverse effects and quality of life in survivors of testicular germ cell tumour

    Publikation: Bidrag til tidsskriftReviewpeer review

Vis graf over relationer

OBJECTIVE: Mitotane is used in the treatment of adrenocortical carcinoma (ACC). Metabolic and hormonal side effects of mitotane, the effect of subsequent treatment with statins and hormones and the effects of discontinuation of mitotane were assessed.

PATIENTS AND METHODS: Fifty patients were included. Lipid profiles, thyroid hormones, sex hormones and adrenal function from first year of mitotane treatment and after cessation were evaluated.

RESULTS: After 6 months of mitotane treatment total cholesterol increased from (median) 5.1 (IQR 4.3 to 5.8) to 7.4 (6.2-9.0) mmol/L, p < .001. LDL, HDL and triglyceride also increased, all p ≤ .03. Three months of treatment with statins decreased total and LDL-cholesterol, and cessation of mitotane led to further reduction in lipids. Plasma thyroxine decreased from 90 (78-111) to 57 (47-63) nmol/L and free thyroxine from 16.0 (13.0-18.3) to 11.7 (10.5-12.6) pmol/L on mitotane, both p < .001, while TSH remained unchanged. Treatment with thyroxin significantly increased plasma thyroxine and free thyroxine and decreased TSH. Cessation of mitotane increased total T4 (p < .001). Mitotane increased plasma SHBG from 36 (22-51) to 189 (85-259) nmol/L and LH from 4.6 (1.6-8.1) to 20.0 (10.0-34.9) IU/L, both p < .001. In males the changes were accompanied by an increase in testosterone from 9.8 (7.2-14.5) to 27.0 (15.3-34.8) nmol/L, p < .03. Fifteen of 24 tested patients regained normal adrenal function 6 (3-16) months after cessation of mitotane.

CONCLUSIONS: Mitotane treatment exerts multiple severe side effects involving both the metabolic and endocrine systems that may require treatment, but the effect appears to be partially reversible.

OriginalsprogEngelsk
TidsskriftClinical Endocrinology
Vol/bind94
Udgave nummer2
Sider (fra-til)141-149
Antal sider9
ISSN0300-0664
DOI
StatusUdgivet - feb. 2021

Bibliografisk note

© 2020 John Wiley & Sons Ltd.

ID: 61373095